In April 2024,Hangzhou Testsea Biotechnology Co., Ltd. underwent its first in-depth interview with the Asia and Africa Center of China Media Group and Iran’s National Television. As a national high-tech enterprise nurtured by Yuhang District of Hangzhou City, Taixi Biotech has showcased its innovative capabilities and global strategic layout in the field of in vitro diagnostics (IVD). The company exemplifies how Chinese biotechnology enterprises can utilize technological advancements and cultural integration to drive growth in the Middle Eastern medical market.
AI-Enabled Halal Detection
He Zenghui, Executive Vice President of Hangzhou Testsea Biotechnology Co., Ltd., stated in an interview that the Sino-US trade war has had a negligible impact on the company. The primary reason for this resilience is the company’s strategic focus on the Southeast Asian market. By establishing robust local cooperation networks in countries such as Thailand and Australia, Testsealabs has developed a supply chain system independent of the North American market, thereby effectively mitigating tariff-related risks.
Yin Xiufei, Partner at Testsealabs and Head of Raw Material Research and Development, highlighted the transformative role of AI computing power in enhancing research and development (R&D) and production processes. Leveraging advanced computational models, the company has significantly reduced R&D uncertainties and optimized resource allocation. Building on these improvements, the team has successfully launched a novel rapid animal-derived test card for food safety, specifically tailored to meet the demands of the Muslim market in the Middle East. This innovative product delivers test results within 5 to 10 minutes, demonstrating exceptional efficiency.
During the on-site demonstration session, both the rapid animal-derived test card and the infectious disease rapid test product exhibited remarkable detection accuracy and sensitivity. These products not only comply with stringent religious requirements but also address critical public health testing needs, thereby establishing a distinct competitive edge for Testsealabs as it expands into the Middle East market.
Co-construction of industry enlightenment value
The case of Testsealabs shows that the success of Chinese IVD enterprises in the Middle East not only relies on technological advantages, but also requires the construction of a trinity ecosystem of “policy – market – culture”. This report by Iran’s state television marks that the influence of Chinese IVD enterprises in the Middle East has moved from “market entry” to “value creation”. In the future, with the deepening of the “Belt and Road Initiative”, more Chinese medical technology enterprises will write new chapters in the blue ocean market of the Middle East.
Post time: Apr-25-2025